{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:28:33Z","timestamp":1793312913775,"version":"4.5.0"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.critrevonc.2024.104424","type":"journal-article","created":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T01:36:25Z","timestamp":1719106585000},"page":"104424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy"],"prefix":"10.1016","volume":"201","author":[{"given":"Martina","family":"Ruglioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Crucitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Irene","family":"Luculli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspare","family":"Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Livia","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mechelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-8934","authenticated-orcid":false,"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Del Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158290","article-title":"Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21Cdkn1a and Pbx1 in Hematopoietic Cells","volume":"11","author":"Abe","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-020-0318-1","article-title":"Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia","volume":"10","author":"Abou Dalle","year":"2020","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104424_bib3","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/leu.2017.82","article-title":"The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a\/16-1 expression","volume":"31","author":"Abraham","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104424_bib4","doi-asserted-by":"crossref","first-page":"11685","DOI":"10.1007\/s11033-022-07977-y","article-title":"Identification of three novel DNMT3A mutations with compromising methylation capacity in human acute myeloid leukaemia","volume":"49","author":"Ali","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.critrevonc.2024.104424_bib5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1186\/s12885-015-1695-x","article-title":"Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia","volume":"15","author":"Al-Jamal","year":"2015","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104424_bib6","doi-asserted-by":"crossref","first-page":"14905","DOI":"10.18632\/oncotarget.3614","article-title":"Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes","volume":"6","author":"Alonso","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104424_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104424_bib8","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/cncr.28705","article-title":"Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations","volume":"120","author":"Alvarado","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41375-022-01798-5","article-title":"Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling","volume":"37","author":"Anderson","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2024.104424_bib10","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2018-99-115183","article-title":"Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant\/p53 Wild-Type Acute Myeloid Leukemia Models","volume":"132","author":"Andreeff","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104424_bib12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104424_bib13","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/cncr.31398","article-title":"Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib14","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/bloodadvances.2021004611","article-title":"Momelotinib is a highly potent inhibitor of FLT3-mutant AML","volume":"6","author":"Azhar","year":"2022","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib15","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/bloodadvances.2021005585","article-title":"European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol","volume":"6","author":"Bataller","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2024.104424_bib17","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2019-125770","article-title":"LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease","volume":"134","author":"Beeharry","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104424_bib18","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1182\/bloodadvances.2019001068","article-title":"LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML","volume":"3","author":"Beeharry","year":"2019","journal-title":"Blood Adv."},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104424_bib19","doi-asserted-by":"crossref","first-page":"7764","DOI":"10.1158\/1078-0432.CCR-04-1895","article-title":"MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia","volume":"11","author":"Benderra","year":"2005","journal-title":"Clin. Cancer Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104424_bib20","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/ajh.25943","article-title":"Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed\/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients","volume":"95","author":"Borthakur","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104424_bib21","doi-asserted-by":"crossref","first-page":"17795","DOI":"10.18632\/oncotarget.14855","article-title":"MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor","volume":"8","author":"Caenepeel","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48687-z","article-title":"The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia","volume":"9","author":"Cao","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib23","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib24","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1074\/jbc.M411974200","article-title":"FLT3\/ITD mutation signaling includes suppression of SHP-1","volume":"280","author":"Chen","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"30","key":"10.1016\/j.critrevonc.2024.104424_bib25","doi-asserted-by":"crossref","first-page":"47018","DOI":"10.18632\/oncotarget.10147","article-title":"Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib26","first-page":"46","article-title":"Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications","volume":"11","author":"Cheng","year":"2008","journal-title":"IDrugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","article-title":"AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations","volume":"106","author":"Choudhary","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood-2006-05-024018","article-title":"Activation mechanisms of STAT5 by oncogenic Flt3-ITD","volume":"110","author":"Choudhary","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1470-2045(18)30240-7","article-title":"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial","volume":"19","author":"Cortes","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib30","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.23345","article-title":"FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Daver","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104424_bib32","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104424_bib33","first-page":"1343","article-title":"A Phase I Study of FLX925, a Dual FLT3 and CDK4\/6 Inhibitor in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)","volume":"130","author":"Daver","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104424_bib34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib36","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2018.208306","article-title":"Kinome expression profiling to target new therapeutic avenues in multiple myeloma","volume":"105","author":"de Boussac","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1586\/17474086.2014.903794","article-title":"RARA fusion genes in acute promyelocytic leukemia: a review","volume":"7","author":"De Braekeleer","year":"2014","journal-title":"Expert Rev. Hematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104424_bib38","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104424_bib41","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","article-title":"Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications","volume":"6","author":"D\u00f6hner","year":"2022","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104424_bib42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40291-021-00568-w","article-title":"MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review","volume":"26","author":"Dong","year":"2022","journal-title":"Mol. Diagn. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104424_bib43","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","article-title":"Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib","volume":"104","author":"Dumas","year":"2019","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104424_bib44","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-20-3114","article-title":"Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in","volume":"27","author":"Dumas","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41375-022-01742-7","article-title":"Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA\/FILO","volume":"37","author":"Dumas","year":"2023","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104424_bib46","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib47","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","article-title":"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers","volume":"72","author":"Dutreix","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104424_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104424_bib49","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/blood.V122.21.2541.2541","article-title":"and Nathalie Javidi-Sharifi and Anupriya Agarwal and Jennifer, B.D.a.I.E.a.J.M.a.T.J.K.a.J.W.T.a.M.W., FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance","volume":"122","author":"Elie Traer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104424_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104424_bib51","first-page":"2258","article-title":"Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3\/tyrosine kinase domain\/F691 mutation","volume":"124","author":"Erratum: Fathi","year":"2018","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104424_bib52","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/s41375-021-01222-4","article-title":"Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field","volume":"35","author":"Falini","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib53","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib54","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bjh.13353","article-title":"A phase I\/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations","volume":"169","author":"Fiedler","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188666","article-title":"The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors","volume":"1877","author":"Friedman","year":"2022","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104424_bib56","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/138920006774832587","article-title":"Cytochrome P450 and anticancer drugs","volume":"7","author":"Fujita","year":"2006","journal-title":"Curr. Drug Metab."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104424_bib58","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood-2004-04-1440","article-title":"Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)\/CXCR4 axis","volume":"105","author":"Fukuda","year":"2005","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.critrevonc.2024.104424_bib59","doi-asserted-by":"crossref","first-page":"16121","DOI":"10.1073\/pnas.1305937110","article-title":"Regulation of human hematopoietic stem cell self-renewal by the microenvironment's control of retinoic acid signaling","volume":"110","author":"Ghiaur","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","article-title":"Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment","volume":"31","author":"Ghiaur","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2024.104424_bib61","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1182\/blood-2023-182466","article-title":"Improvement in Survival of Patients with FLT3 Mutated Acute Myeloid Leukemia: Results from a Retrospective Canadian Cohort","volume":"142","author":"Ghosh","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib62","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104424_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500221","article-title":"Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia","volume":"1","author":"Green","year":"2015","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib64","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.onc.1203354","article-title":"Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines","volume":"19","author":"Hayakawa","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2024.104424_bib65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2005-06-2469","article-title":"Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain","volume":"107","author":"Heidel","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12185-015-1908-8","article-title":"Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells","volume":"103","author":"Hirade","year":"2016","journal-title":"Int J. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib67","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2011-11-393066","article-title":"The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells","volume":"119","author":"Hospital","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104424_bib68","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1182\/bloodadvances.2021004965","article-title":"CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes","volume":"5","author":"Huang","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2024.104424_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.782065","article-title":"LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K\/Akt Signaling Pathway","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib70","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2141.2004.05145.x","article-title":"The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors","volume":"127","author":"Hunter","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib71","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/14756366.2021.2020772","article-title":"Rational design and synthesis of 2-(1","volume":"37","author":"Im","year":"2022","journal-title":"J. Enzym. Inhib. Med Chem."},{"key":"10.1016\/j.critrevonc.2024.104424_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.923809","article-title":"Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms","volume":"12","author":"Ip","year":"2022","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib73","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.exphem.2009.12.003","article-title":"Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts","volume":"38","author":"Jacobi","year":"2010","journal-title":"Exp. Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib74","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/s41375-022-01650-w","article-title":"Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603\/RATIFY trial","volume":"36","author":"Jahn","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2024.104424_bib75","article-title":"FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells","volume":"8","author":"Javidi-Sharifi","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.critrevonc.2024.104424_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-023-01897-x","article-title":"FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4\/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML","author":"Jia","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib77","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1172\/JCI127907","article-title":"Targeting AML-associated FLT3 mutations with a type I kinase inhibitor","volume":"130","author":"Jones","year":"2020","journal-title":"J. Clin. Invest"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib78","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib79","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/leu.2013.342","article-title":"Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML","volume":"28","author":"Kampen","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib80","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/1078-0432.CCR-17-1629","article-title":"Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation","volume":"24","author":"Kapoor","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib81","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-0609.2010.01556.x","article-title":"FLT3\/\u200aITD regulates leukaemia cell adhesion through \u03b14\u03b21 integrin and Pyk2 signalling","volume":"86","author":"Katsumi","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104424_bib82","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2009-03-209999","article-title":"Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome","volume":"114","author":"Kayser","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104424_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.612880","article-title":"Mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2024.104424_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 Mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib85","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jcyt.2021.10.006","article-title":"Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation","volume":"24","author":"Khanolkar","year":"2022","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib86","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2004-05-2006","article-title":"Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival","volume":"105","author":"Kim","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104424_bib87","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40265-017-0779-0","article-title":"Midostaurin: First Global Approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071737","article-title":"CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib89","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/sj.leu.2401130","article-title":"Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product","volume":"12","author":"Kiyoi","year":"1998","journal-title":"Leukemia"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2024.104424_bib90","first-page":"7","article-title":"FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION","volume":"77","author":"Kiyoi","year":"2015","journal-title":"Nagoya J. Med Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104424_bib91","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib92","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0092-8674(95)90351-8","article-title":"Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals","volume":"80","author":"Klingm\u00fcller","year":"1995","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib93","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","article-title":"A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML","volume":"129","author":"Knapper","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib94","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","article-title":"Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia","volume":"7","author":"Lachowiez","year":"2023","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib95","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjh.16456","article-title":"Dissecting the role of the CXCL12\/CXCR4 axis in acute myeloid leukaemia","volume":"189","author":"Ladikou","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104424_bib96","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib97","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3324\/haematol.2018.205955","article-title":"Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia","volume":"104","author":"Levine","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104424_bib98","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104424_bib99","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2023010619","article-title":"A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia","author":"Levis","year":"2024","journal-title":"Blood Adv."},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104424_bib100","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib101","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1111\/bcp.14022","article-title":"Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite","volume":"85","author":"Li","year":"2019","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.critrevonc.2024.104424_bib102","doi-asserted-by":"crossref","first-page":"1086846","DOI":"10.3389\/fonc.2023.1086846","article-title":"FLT3-TKD in the prognosis of patients with acute myeloid leukemia: A meta-analysis","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2024.104424_bib103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-319-91439-8_2","article-title":"Dasatinib","volume":"212","author":"Lindauer","year":"2018","journal-title":"Recent Results Cancer Res"},{"issue":"39","key":"10.1016\/j.critrevonc.2024.104424_bib104","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib105","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.2018.191809","article-title":"Impact of","volume":"104","author":"Liu","year":"2019","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104424_bib106","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood.2019003538","article-title":"FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia","volume":"135","author":"Long","year":"2020","journal-title":"Blood"},{"issue":"7-8","key":"10.1016\/j.critrevonc.2024.104424_bib107","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000478018","article-title":"Liquid Biopsy: Current Status and Future Perspectives","volume":"40","author":"Mader","year":"2017","journal-title":"Oncol. Res Treat."},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104424_bib108","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/blood-2011-06-363960","article-title":"Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.","volume":"119","author":"Man","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104424_bib109","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2013-07-512194","article-title":"A novel tescalcin-sodium\/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML","volume":"123","author":"Man","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104424_bib110","first-page":"295","article-title":"Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia","volume":"130","author":"McMahon","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104424_bib111","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Cancer Discov."},{"issue":"508","key":"10.1016\/j.critrevonc.2024.104424_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8828","article-title":"Overcoming adaptive therapy resistance in AML by targeting immune response pathways","volume":"11","author":"Melgar","year":"2019","journal-title":"Sci. Transl. Med"},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2024.104424_bib113","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.cad.0000361534.44052.c5","article-title":"Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib","volume":"21","author":"Mena","year":"2010","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib114","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V97.1.89","article-title":"Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia","volume":"97","author":"Meshinchi","year":"2001","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104424_bib115","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-08-1123","article-title":"Structural and functional alterations of FLT3 in acute myeloid leukemia","volume":"15","author":"Meshinchi","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib116","first-page":"15","article-title":"and","volume":"15","author":"Naseem","year":"2021","journal-title":"Int J. Hematol. Oncol. Stem Cell Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074653","article-title":"Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication","volume":"8","author":"Natarajan","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib118","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib119","doi-asserted-by":"crossref","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"O'Donnell","year":"2017","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib120","first-page":"6","article-title":"FLT3 Gene Involvement in B-cell acute lymphoblastic leukemia (B-ALL)","volume":"47","author":"Okabe","year":"2021","journal-title":"J. Assoc. Genet Technol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib121","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/bloodadvances.2020004136","article-title":"Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1","volume":"6","author":"O\u00f1ate","year":"2022","journal-title":"Blood Adv."},{"issue":"47","key":"10.1016\/j.critrevonc.2024.104424_bib122","doi-asserted-by":"crossref","first-page":"28356","DOI":"10.1074\/jbc.A114.568287","article-title":"Internal tandem duplication mutations in FLT3 gene augment chemotaxis to Cxcl12 protein by blocking the down-regulation of Rho-associated kinase via the Cxcl12\/Cxcr4 signaling axis","volume":"290","author":"Onishi","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib123","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/10428190290026277","article-title":"P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype","volume":"43","author":"Pallis","year":"2002","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib124","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1046\/j.1365-2141.2003.04210.x","article-title":"Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications","volume":"120","author":"Pallis","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib125","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/blood.V95.9.2897.009k14_2897_2904","article-title":"P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway","volume":"95","author":"Pallis","year":"2000","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104424_bib126","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/leu.2015.147","article-title":"Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia","volume":"29","author":"Park","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104424_bib127","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1038\/s41375-020-0858-1","article-title":"Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms","volume":"34","author":"Patel","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104424_bib128","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1080\/10428194.2017.1399312","article-title":"The importance of FLT3 mutational analysis in acute myeloid leukemia","volume":"59","author":"Patnaik","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104424_bib129","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib130","doi-asserted-by":"crossref","first-page":"265.e1","DOI":"10.1016\/j.jtct.2022.12.006","article-title":"Outcomes in Patients with FLT3-Mutated Relapsed\/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy","volume":"29","author":"Perl","year":"2023","journal-title":"Transpl. Cell Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104424_bib131","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1158\/1535-7163.MCT-12-0129","article-title":"Breakdown of the FLT3-ITD\/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors","volume":"11","author":"Pietschmann","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib132","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2006-05-023804","article-title":"Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways","volume":"109","author":"Piloto","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104424_bib133","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccr.2014.01.022","article-title":"SYK is a critical regulator of FLT3 in acute myeloid leukemia","volume":"25","author":"Puissant","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib134","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41420-023-01317-0","article-title":"The GSK3\u03b2\/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors","volume":"9","author":"Qiu","year":"2023","journal-title":"Cell Death Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib135","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clml.2019.08.006","article-title":"Prognostic Significance of bcr-1 and bcr-3 Isoforms of PML-RARA and FLT3-ITD in Patients With Acute Promyelocytic Leukemia","volume":"20","author":"Rasekh","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104424_bib136","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2010-08-301416","article-title":"SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control","volume":"120","author":"Reddy","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib137","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2991\/chi.k.200714.001","article-title":"Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation","volume":"2","author":"Ricci","year":"2020","journal-title":"Clin. Hematol. Int"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104424_bib138","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood-2004-02-0566","article-title":"Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia","volume":"104","author":"Rombouts","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib139","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","article-title":"Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results","volume":"36","author":"R\u00fccker","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib140","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1038\/s41375-020-01077-1","article-title":"Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo","volume":"35","author":"Rummelt","year":"2021","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104424_bib141","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1002\/cncr.32387","article-title":"Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia","volume":"125","author":"Sasaki","year":"2019","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104424_bib142","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104424_bib143","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.4161\/cc.8.16.9355","article-title":"The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin","volume":"8","author":"Schittenhelm","year":"2009","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib144","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.lab.2005.03.005","article-title":"Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia","volume":"145","author":"Scholl","year":"2005","journal-title":"J. Lab Clin. Med"},{"issue":"Supplement 1","key":"10.1016\/j.critrevonc.2024.104424_bib145","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood-2023-187725","article-title":"The Shifting Prognosis of FLT3 Mutations in Acute Myeloid Leukemia in the Era of Targeted Therapy: A Real-World Study Using Large-Scale Electronic Health Record Data","volume":"142","author":"Schwede","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib146","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00280-022-04448-w","article-title":"Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)","volume":"90","author":"Sechaud","year":"2022","journal-title":"Cancer Chemother. Pharm."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104424_bib147","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3324\/haematol.2018.191650","article-title":"MDM2- and FLT3-inhibitors in the treatment of","volume":"103","author":"Seipel","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104424_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106460","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and FLT3 rearrangement","volume":"99","author":"Shao","year":"2020","journal-title":"Leuk. Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib149","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041177","article-title":"NPM 1 Mutations in AML-The Landscape in 2023","volume":"15","author":"Sharma","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104424_bib150","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/bloodadvances.2019001156","article-title":"Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv."},{"issue":"10147","key":"10.1016\/j.critrevonc.2024.104424_bib151","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104424_bib152","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1182\/blood-2023-187902","article-title":"Real-World Data for FLT3-Mutated Acute Myeloid Leukemia Patients Treated in Resource-Constrained Settings","volume":"142","author":"Silva","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib153","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7397","key":"10.1016\/j.critrevonc.2024.104424_bib154","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104424_bib155","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104424_bib156","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib157","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","article-title":"Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis","volume":"130","author":"Smith","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104424_bib158","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/17512433.2023.2174523","article-title":"Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape","volume":"16","author":"Solana-Altabella","year":"2023","journal-title":"Expert Rev. Clin. Pharm."},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104424_bib159","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2016-10-687830","article-title":"Role of RUNX1 in hematological malignancies","volume":"129","author":"Sood","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib160","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc840","article-title":"Core-binding factors in haematopoiesis and leukaemia","volume":"2","author":"Speck","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib161","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2005-08-3453","article-title":"Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia","volume":"107","author":"Stirewalt","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib162","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41417-021-00329-1","article-title":"Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias","volume":"29","author":"Su","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"Suppl 8","key":"10.1016\/j.critrevonc.2024.104424_bib163","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.21037\/atm.2019.12.97","article-title":"Clonal hematopoiesis: background player in plasma cell-free DNA variants","volume":"7","author":"Sun","year":"2019","journal-title":"Ann. Transl. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104424_bib164","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2005-04-1733","article-title":"Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia","volume":"106","author":"Suzuki","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104424_bib165","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2012.114","article-title":"Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia","volume":"26","author":"Swords","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2024.104424_bib166","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib167","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.critrevonc.2024.104424_bib168","doi-asserted-by":"crossref","first-page":"1164517","DOI":"10.3389\/fonc.2023.1164517","article-title":"Liquid biopsy in hematological malignancies: current and future applications","volume":"13","author":"Talotta","year":"2023","journal-title":"Front Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104424_bib169","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3324\/haematol.2019.240705","article-title":"Dasatinib response in acute myeloid leukemia is correlated with FLT3\/ITD, PTPN11 mutations and a unique gene expression signature","volume":"105","author":"Tavor","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104424_bib170","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.604391","article-title":"Real-Time Molecular Monitoring in Acute Myeloid Leukemia With Circulating Tumor DNA","volume":"8","author":"Thakral","year":"2020","journal-title":"Front Cell Dev. Biol."},{"issue":"26","key":"10.1016\/j.critrevonc.2024.104424_bib171","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1021\/acs.jpcb.9b01567","article-title":"Activation and Inactivation of the FLT3 Kinase: Pathway Intermediates and the Free Energy of Transition","volume":"123","author":"Todde","year":"2019","journal-title":"J. Phys. Chem. B"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104424_bib172","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1021\/acs.jcim.0c00544","article-title":"Pattern and Dynamics of FLT3 Duplications","volume":"60","author":"Todde","year":"2020","journal-title":"J. Chem. Inf. Model"},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104424_bib173","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","article-title":"FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia","volume":"76","author":"Traer","year":"2016","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib174","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18061115","article-title":"The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis","volume":"18","author":"Tsapogas","year":"2017","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib175","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13073-021-00898-8","article-title":"Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients","volume":"13","author":"Tsui","year":"2021","journal-title":"Genome Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib176","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/cbdd.13169","article-title":"Insight into the inhibitor discrimination by FLT3 F691L","volume":"91","author":"Verma","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib177","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2011-01-329532","article-title":"Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex","volume":"118","author":"Verstraete","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib178","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/17474086.2018.1475225","article-title":"Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome","volume":"11","author":"Visani","year":"2018","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib179","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00204-021-03174-1","article-title":"Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3","volume":"96","author":"Wachholz","year":"2022","journal-title":"Arch. Toxicol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib180","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3109\/10428194.2015.1135435","article-title":"Midostaurin, bortezomib and MEC in relapsed\/refractory acute myeloid leukemia","volume":"57","author":"Walker","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib181","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2007-02-071266","article-title":"Pharmacologic inhibition of CDK4\/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia","volume":"110","author":"Wang","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib182","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med Chem."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104424_bib183","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1021\/acs.jmedchem.0c02247","article-title":"Discovery of a Potent and Selective FLT3 Inhibitor","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med Chem."},{"issue":"16\\_suppl","key":"10.1016\/j.critrevonc.2024.104424_bib184","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1200\/JCO.2022.40.16_suppl.7007","article-title":"Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML","volume":"40","author":"Wang","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104424_bib185","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11864-023-01090-3","article-title":"Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia","volume":"24","author":"Wang","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104424_bib186","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2013.4","article-title":"A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop","volume":"2","author":"Ware","year":"2013","journal-title":"Oncogenesis"},{"issue":"32","key":"10.1016\/j.critrevonc.2024.104424_bib187","doi-asserted-by":"crossref","first-page":"52026","DOI":"10.18632\/oncotarget.19036","article-title":"Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase","volume":"8","author":"Weisberg","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib188","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","article-title":"Pharmacologic inhibition of STAT5 in acute myeloid leukemia","volume":"32","author":"Wingelhofer","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib189","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/leu.2016.297","article-title":"MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia","volume":"31","author":"Xu","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib190","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/cncr.31295","article-title":"Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"124","author":"Xuan","year":"2018","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104424_bib191","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104424_bib192","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104424_bib193","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib194","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12935-023-03000-x","article-title":"Combination strategies to overcome drug resistance in FLT","volume":"23","author":"Yang","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bjh.12599","article-title":"Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase","volume":"164","author":"Yang","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib196","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7150\/thno.46593","article-title":"LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia","volume":"11","author":"Yu","year":"2021","journal-title":"Theranostics"},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104424_bib197","article-title":"DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients","volume":"95","author":"Yuan","year":"2016","journal-title":"Med. (Baltim. )"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib198","doi-asserted-by":"crossref","DOI":"10.3390\/genes11060649","article-title":"Nucleophosmin 1 Mutations in Acute Myeloid Leukemia","volume":"11","author":"Zarka","year":"2020","journal-title":"Genes (Basel)"},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104424_bib199","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML","volume":"113","author":"Zeng","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib200","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1074\/mcp.M900452-MCP200","article-title":"A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia","volume":"9","author":"Zhang","year":"2010","journal-title":"Mol. Cell Proteom."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib201","first-page":"675","article-title":"FLT3 and CDK4\/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia","volume":"41","author":"Zhang","year":"2014","journal-title":"J. Pharm. Pharm."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104424_bib202","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1158\/0008-5472.CAN-15-1580","article-title":"The Dual MEK\/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations","volume":"76","author":"Zhang","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104424_bib203","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41467-018-08263-x","article-title":"Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104424_bib204","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.32534","article-title":"Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2024.104424_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113776","article-title":"Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor","volume":"225","author":"Zhang","year":"2021","journal-title":"Eur. J. Med Chem."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104424_bib206","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s13402-022-00703-7","article-title":"Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines","volume":"45","author":"Zhang","year":"2022","journal-title":"Cell Oncol. (Dordr. )"},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104424_bib207","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 Enzymes and Drug Metabolism in Humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104424_bib208","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejmech.2018.06.010","article-title":"Discovery of the selective and efficacious inhibitors of FLT3 mutations","volume":"155","author":"Zhi","year":"2018","journal-title":"Eur. J. Med Chem."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104424_bib209","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1182\/blood-2008-05-156422","article-title":"Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML","volume":"113","author":"Zhou","year":"2009","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T08:47:10Z","timestamp":1728290830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":209,"alternative-id":["S1040842824001677"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104424","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104424"}}